Zafgen, Inc. Information

Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is a well capitalized, bringing together leading experts in metabolic disease to address the underserved population of people with severe obesity. We are aligned with obese patients and are committed to advancing medicines treating the underlying biological mechanisms that create and sustain obesity. We aspire to increase the overall health and quality of life for patients and to dispel the stigma that obesity is a “lifestyle choice,” and not a valid disease. Zafgen is pioneering novel obesity therapeutics that directly target fat metabolism to help the body regain and sustain a lean, healthy state. The company’s approach focuses on restoring control of key metabolic processes by inhibiting Methionine Aminopeptidase 2 (MetAP2) activity, releasing stored fat which then is used by the body as fuel. Founded in 2005 and located in Cambridge, MA, our management team has best-in-class experience in the field of metabolic disease and the function of MetAP2 inhibitors. We are advancing novel therapeutics for patients suffering from severe obesity and related disorders, and are building for the long-term by adding highly regarded professionals to our team. For more information, visit www.zafgen.com.